Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752841 | 0.92 | GSK3B (0.46) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16752844 | 0.92 | GSK3B (0.46) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16769262 | 0.92 | GSK3B (0.46) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16752848 | 0.92 | GSK3B (0.46) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16752809 | 0.89 | GSK3B (0.48) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16752811 | 0.89 | GSK3B (0.48) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16752808 | 0.89 | GSK3B (0.48) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| SCHEMBL16769268 | 0.88 | MAP2K4 (0.44) | MAPK1GSK3BHDAC6 | |
| Sulfuric Acid SCHEMBL16752805 | 0.86 | GSK3B (0.45) | MAPK1FGFR2FGFR1GSK3BHDAC6 | |
| Sulfuric Acid SCHEMBL16752806 | 0.86 | GSK3B (0.45) | MAPK1FGFR2FGFR1GSK3BHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | MAPK1 2761/4885FGFR2 4023/4885FGFR1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.